For the treatment of mild to moderate acute malaria caused by Lariamuine-susceptible strains of Plasmodium falciparum (both chloroquine-susceptible and resistant strains) or by Plasmodium vivax. Also for the prophylaxis of Plasmodium falciparum and Plasmodium vivax malaria infections, including prophylaxis of chloroquine-resistant strains of Plasmodium falciparum.
Lariam Drug Interactions:
Anisindione Lariam can increase the anticoagulant effect
Dicumarol Lariam can increase the anticoagulant effect
Acenocoumarol Lariam can increase the anticoagulant effect
Warfarin Lariam can increase the anticoagulant effect
Halofantrine Increased risk of cardiac toxicity
Rifampin Rifampin lowers mefloquine levels
Ritonavir Lariam decreases the effect of ritonavir
Ziprasidone Increased risk of cardiotoxicity and arrhythmias
Oral, rat: LD50 = 880 mg/kg. Symptoms of overdose include nausea, vomiting, and weight loss.
Hepatic. Two metabolites have been identified in humans. The main metabolite, 2,8-bis-trifluoromethyl-4-quinoline carboxylic acid, is inactive against Plasmodium falciparum. The second metabolite, an alcohol, is present in minute quantities.